Back to Browse Journals » Drug Design, Development and Therapy » Volume 4

Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension

Authors Gautam V Ramani, Myung H Park

Published Date May 2010 Volume 2010:4 Pages 61—70

DOI http://dx.doi.org/10.2147/DDDT.S6208

Published 6 May 2010

Gautam V Ramani, Myung H Park

University of Maryland, Baltimore, MD, USA

Abstract: Sildenafil is an orally administered phosphodiesterase type 5 inhibitor that is approved for the treatment of pulmonary arterial hypertension (PAH). The hemodynamic effects of sildenafil are mitigated primarily via potentiating the effects of endogenous nitric oxide, leading to smooth muscle cell relaxation and reductions in pulmonary arterial pressures and pulmonary vascular resistance. When added to standard background therapy in patients with idiopathic or associated PAH from congenital heart disease, anorexigen use, or connective tissue disease, sildenafil treatment results in improved exercise capacity as measured by 6 minute walk distance, improved hemodynamics, and favorable changes in quality of life. Sildenafil use is contraindicated with concomitant nitrate administration, and caution should be exercised when used in combination with antihypertensive agents due to risks of precipitating hypotension. Side effects are generally mild, and include flushing, headaches, and epistaxis. The combination of sildenafil with intravenous epoprostenol is safe and well tolerated, and further improves exercise capacity. Sildenafil is approved only for treatment of PAH, and although emerging data suggest a potential role in treating other types of pulmonary hypertension, larger trials are required to confirm these findings.

Keywords: sildenafil, pulmonary arterial hypertension, phosphodiesterase type 5 inhibitor

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Pleiotropic vasoprotective effects of statins: The chicken or the egg?

Dimitrios Kirmizis, Dimitrios Chatzidimitriou

Drug Design, Development and Therapy 2009, 3:191-204

Published Date: 10 June 2009

Continuation treatment of major depressive disorder: is there a case for duloxetine?

Trevor R Norman, James S Olver

Drug Design, Development and Therapy 2010, 4:19-31

Published Date: 12 February 2010

Health literacy and health seeking behavior among older men in a middle-income nation

Paul A Bourne, Chloe Morris, Christopher AD Charles, et al

Patient Related Outcome Measures 2010, 1:39-49

Published Date: 26 May 2010

Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy

Aarat M Patel, Larry W Moreland

Drug Design, Development and Therapy 2010, 4:263-278

Published Date: 1 October 2010

Epigenomics in cancer management

Fabricio F Costa

Cancer Management and Research 2010, 2:255-265

Published Date: 27 October 2010

Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections

Emily Zoller, Connie Valente, Kyle Baker, et al

Drug Design, Development and Therapy 2010, 4:299-311

Published Date: 4 November 2010

Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi

Sapi E, Kaur N, Anyanwu S, Luecke DF, Datar A, Patel S, Rossi M, Stricker RB

Infection and Drug Resistance 2011, 4:97-113

Published Date: 3 May 2011